Demand for services sees biotech firm move home

Edinburgh-based firm Synpromics is moving to a new home at the Roslin Innovation Centre to meet surging global demand for its world-leading gene control technology.

Synpromics was founded in 2010 to commercialise technology developed by chief scientific officer Dr Michael Roberts in the “highly disruptive” field of synthetic biology – which gives researchers the ability to create man-made DNA sequences to aid the development of cures for conditions such as haemophilia and hereditary blindness.

The firm is now lauding the next step in its growth and development with the move to the new site, after signing deals to provide gene therapy and bioprocessing with huge clients. The ground-breaking developments allow for researchers to create gene “promoters” which are not naturally occurring with DNA.

The Roslin Innovation Centre, adjacent to Edinburgh Uni’s Bush Campus, offers mixed-use space, and the firm will occupy both office and lab space.